We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

3 hedge funds and large institutions have $176K invested in ELITE PHARMACEUTICAL in 2014 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $170K → $176K (+$6.09K)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
Geneva Advisors
Illinois
$119K – – –
Janney Montgomery Scott
2
Janney Montgomery Scott
Pennsylvania
$31.9K – – –
JAFL
3
Jay A. Fishman Ltd
Michigan
$25.5K – – –

ELI Hedge Fund Activity: Q2 2014 in Review

3 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2014, worth a combined $176K — up 3.6% from $170K a quarter earlier.

Fund positioning in ELI was balanced in Q2 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $176K of ELITE PHARMACEUTICAL stock for Q2 2014, up 3.6% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2014 and 0 closed out.

Based on aggregated 13F filings for Q2 2014.